Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism

American Journal of Translational Research

Volumn 3, Issue 4, 2011, Pages 374-382

  Azmi, Asfar S ^a   Ali, Shadan ^a   Banerjee, Sanjeev ^a   Bao, Bin ^a   Maitah, Mai''n ^a   Padhye, Subhash ^a   Philip, Philip A ^a   Mohammad, Ramzi M ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; C Myc; CDF; Curcumin; Network modeling; P53; P73; Pancreatic cancer; Systems biology

Indexed keywords

CURCUMIN; CURCUMIN DIFLUORINATED; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P73; SMALL INTERFERING RNA; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; ONCOGENE C MYC; PANCREAS CANCER; RNA EXTRACTION; WESTERN BLOTTING;

CITRUS MACROPHYLLA;

EID: 80051727417     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pujol A, Mosca R, Farres J, and Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010; 31(3): 115-123.
2. Wang Z, Bordas V, and Deisboeck TS. Discover-ing Molecular Targets in Cancer with Multiscale Modeling. Drug Dev Res 2011; 72(1): 45-52.
3. Spiro Z, Kovacs IA, and Csermely P. Drug-therapy networks and the prediction of novel drug targets. J Biol 2008; 7(6): 20
4. Cho CR, Labow M, Reinhardt M, van OJ, and Peitsch MC. The application of systems biology to drug discovery. Curr Opin Chem Biol 2006; 10(4): 294-302.
5. Arrell DK and Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther 2010; 88(1): 120-125.
6. Azmi AS, Wang Z, Philip PA, Mohammad RM, and Sarkar FH. Proof of concept: network and systems biology approaches aid in the discov-ery of potent anticancer drug combinations. Mol Cancer Ther 2010; 9(12): 3137-3144.
7. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, and Sarkar FH. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70(9): 3606-3617.
8. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Baner-jee S, Aboukameel A, Padhye S, Philip PA, and Sarkar FH. Anti-tumor activity of a novel com-pound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6(3): e17850
9. Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, Li J, Dou QP, and Sarkar FH. Fluorocurcumins as cyclooxygenase-2 in-hibitor: molecular docking, pharmacokinet-ics and tissue distribution in mice. Pharm Res 2009; 26(11): 2438-2445.
10. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, and Majumdar AP. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011; 28(4): 827-838.
11. Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, and Sarkar FH. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 2011;
12. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, and Mohammad RM. Network Mod-eling of MDM2 Inhibitor-Oxaliplatin Combina-tion Reveals Biological Synergy in wt-p53 solid tumors. Oncotarget 2011;
13. Cole MD and Henriksson M. 25 years of the c-Myc oncogene. Semin Cancer Biol 2006; 16(4): 241
14. Bishop JM, Courtneidge SA, Levinson AD, Op-permann H, Quintrell N, Sheiness DK, Weiss SR, and Varmus HE. Origin and function of avian retrovirus transforming genes. Cold Spring Harb Symp Quant Biol 1980; 44 Pt 2, 919-930.
15. Dominguez-Sola D and la-Favera R. PINning down the c-Myc oncoprotein. Nat Cell Biol 2004; 6(4): 288-289.
16. Stoneley M and Willis AE. Aberrant regulation of translation initiation in tumorigenesis. Curr Mol Med 2003; 3(7): 597-603.
17. arcon-Vargas D, Tansey WP, and Ronai Z. Regu-lation of c-myc stability by selective stress con-ditions and by MEKK1 requires aa 127-189 of c-myc. Oncogene 2002; 21(28): 4384-4391.
18. Bhatia K, Spangler G, Gaidano G, Hamdy N, la-Favera R, and Magrath I. Mutations in the cod-ing region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lym-phomas. Blood 1994; 84(3): 883-888.
19. Eilers M and Eisenman RN. Myc's broad reach. Genes Dev 2008; 22(20): 2755-2766.
20. Kowalik TF, DeGregori J, Leone G, Jakoi L, and Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9(2): 113-118.
21. Debbas M and White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 1993; 7(4): 546-554.
22. Askew DS, Ihle JN, and Cleveland JL. Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is domi-nant to the suppression of apoptosis by inter-leukin-3 or erythropoietin. Blood 1993; 82(7): 2079-2087.
23. Hoglund A, Nilsson LM, Forshell LP, MacLean KH, and Nilsson JA. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113(18): 4281-4288.
24. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, and Zam-betti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic path-ways. Cancer Cell 2003; 4(4): 321-328.
25. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, and Green DR. The BCL-2 family reunion. Mol Cell 2010; 37(3): 299-310.
26. Eischen CM, Weber JD, Roussel MF, Sherr CJ, and Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13(20): 2658-2669.
27. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, and Roussel MF. Myc signaling via the ARF tumor suppressor regu-lates p53-dependent apoptosis and immortali-zation. Genes Dev 1998; 12(15): 2424-2433.
28. Zemskova M. p53-dependent induction of pros- tate cancer cell senescence by the PIM1 pro-tein kinase. 2010;
29. Melino G. p73, the assistant guardian of the genome? Ann N Y Acad Sci 2003; 1010: 9-15.
30. Melino G, De L, V, and Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2(8): 605-615.
31. Melino G, Lu X, Gasco M, Crook T, and Knight RA. Functional regulation of p73 and p63: de-velopment and cancer. Trends Biochem Sci 2003; 28(12): 663-670.
32. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, and Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010; 46(6): 1122-1131.
33. Zaika A, Irwin M, Sansome C, and Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001; 276(14): 11310-11316.
34. Millan MJ. Multi-target strategies for the im-proved treatment of depressive states: Concep-tual foundations and neuronal substrates, drug discovery and therapeutic application. Pharma-col Ther 2006; 110(2): 135-370.
35. Frantz S. Drug discovery: playing dirty. Nature 2005; 437(7061): 942-943.